We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+12.69%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11B
AUM Growth
+$1.14B
Cap. Flow
+$217M
Cap. Flow %
1.96%
Top 10 Hldgs %
40.32%
Holding
138
New
6
Increased
33
Reduced
26
Closed
8

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$152M
2
GILD icon
Gilead Sciences
GILD
+$129M
3
WCG
Wellcare Health Plans, Inc.
WCG
+$102M
4
PBYI icon
Puma Biotechnology
PBYI
+$81.9M
5
ESRX
Express Scripts Holding Company
ESRX
+$72M

Top Sells

Rank Stock Value
1
MOH icon
Molina Healthcare
MOH
+$168M
2
SHPG
Shire pic
SHPG
+$85.9M
3
MCK icon
McKesson
MCK
+$66.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$66.1M
5
COO icon
Cooper Companies
COO
+$55.3M

Sector Composition

Rank Sector Weight
1 Healthcare 90.58%
2 Financials 0.18%
3 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$130B
$577M 5.23%
8,395,000
-273,100
-3% -$18M
AMGN icon
2
Amgen
AMGN
$212B
$474M 4.29%
2,921,000
-92,000
-3% -$14.5M
BSX icon
3
Boston Scientific
BSX
$68.5B
$451M 4.08%
24,430,900
+423,700
+2% +$7.59M
AGN
4
DELISTED
Allergan plc
AGN
$445M 4.03%
1,424,715
-18,600
-1% -$5.54M
BIIB icon
5
Biogen
BIIB
$30.4B
$442M 4%
1,442,500
+135,100
+10% +$38.8M
ABBV icon
6
AbbVie
ABBV
$465B
$441M 4%
7,448,500
+505,300
+7% +$29.1M
CELG
7
DELISTED
Celgene Corp
CELG
$439M 3.98%
3,665,450
+72,450
+2% +$8.38M
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$434M 3.93%
2,275,100
+48,500
+2% +$8.47M
HCA icon
9
HCA Healthcare
HCA
$92.8B
$403M 3.65%
5,955,600
+117,700
+2% +$8.21M
GILD icon
10
Gilead Sciences
GILD
$167B
$346M 3.14%
3,421,400
+1,237,000
+57% +$129M
INCY icon
11
Incyte
INCY
$26B
$307M 2.78%
2,832,978
+92,000
+3% +$10.3M
IPXL
12
DELISTED
Impax Laboratories, Inc.
IPXL
$285M 2.58%
6,664,100
– –
REGN icon
13
Regeneron Pharmaceuticals
REGN
$72.9B
$262M 2.37%
483,000
-4,700
-1% -$2.55M
RLYP
14
DELISTED
RELYPSA INC COM
RLYP
$210M 1.9%
7,400,000
– –
HNT
15
DELISTED
HEALTH NET INC
HNT
$205M 1.85%
2,988,800
-409,000
-12% -$26.2M
WMGI
16
DELISTED
Wright Medical Group Inc
WMGI
$199M 1.81%
8,245,111
+103,111
+1% +$2.23M
TMO icon
17
Thermo Fisher Scientific
TMO
$214B
$196M 1.77%
1,380,000
+16,000
+1% +$2.13M
ESRX
18
DELISTED
Express Scripts Holding Company
ESRX
$191M 1.73%
2,182,000
+840,000
+63% +$72M
PBYI icon
19
Puma Biotechnology
PBYI
$406M
$176M 1.59%
2,238,825
+1,043,325
+87% +$81.9M
VTRS icon
20
Viatris
VTRS
$20.8B
$171M 1.55%
+3,157,000
New +$152M
ILMN icon
21
Illumina
ILMN
$29.2B
$168M 1.52%
901,556
-281,672
-24% -$45.5M
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$167M 1.51%
1,120,000
– –
TEVA icon
23
Teva Pharmaceuticals
TEVA
$36.9B
$161M 1.45%
2,446,000
+247,000
+11% +$15.3M
ISEE
24
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$158M 1.43%
2,011,500
+88,000
+5% +$5.09M
NBIX icon
25
Neurocrine Biosciences
NBIX
$18.4B
$142M 1.29%
2,514,974
-1,301,076
-34% -$66.1M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2015 Portfolio in Review

As of Q4 2015, OrbiMed held 138 positions worth $11B, up 11% from $9.91B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q4 2015 filing shows 6 new, 33 increased, 26 reduced and 8 closed positions. Its largest new stake was Viatris: 3,157,000 shares worth $171M. The largest sale was Molina Healthcare, an estimated $168M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q4 2015 buy was Viatris: 3,157,000 shares worth $171M.
  • OrbiMed added most to Gilead Sciences in Q4 2015, an estimated $129M increase.
  • OrbiMed's biggest Q4 2015 reduction was Molina Healthcare, cutting an estimated $168M.
  • OrbiMed fully exited Chimerix, Inc. in Q4 2015, selling an estimated $39M.
  • OrbiMed's ten largest holdings make up 40% of its $11B portfolio in Q4 2015.
  • OrbiMed opened 6 new positions and closed 8 in Q4 2015.
  • OrbiMed's portfolio value rose 11% quarter-over-quarter to $11B.

Based on OrbiMed's 13F filing for Q4 2015, filed 16 Feb 2016.